Eyenovia Provides Manufacturing Update and Announces Appointment of Bren Kern as SVP of Manufacturing and Operations
July 18, 2022 08:00 ET
|
Eyenovia, Inc.
NEW YORK, July 18, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of late-stage microdose array print (MAP™)...
Eyenovia Announces Appointments of Dr. Ellen Strahlman and Dr. Ram Palanki as New and Independent Members of its Board of Directors
July 07, 2022 08:00 ET
|
Eyenovia, Inc.
NEW YORK, July 07, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of late-stage microdose array print (MAP™)...
Eyenovia Strategic Partner Arctic Vision Enrolls First Patient in Phase III Clinical Trial of ARVN003 (MicroLine) for Presbyopia in China
July 06, 2022 08:00 ET
|
Eyenovia, Inc.
NEW YORK, July 06, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of late-stage microdose array print (MAP™)...
UPDATE: Eyenovia Announces Virtual 2022 Annual Meeting of Stockholders
June 09, 2022 10:09 ET
|
Eyenovia, Inc.
NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) investigational...
Eyenovia Announces Virtual 2022 Annual Meeting of Stockholders
June 09, 2022 08:00 ET
|
Eyenovia, Inc.
NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) investigational...
Eyenovia Announces Planned Chief Executive Officer Transition
June 07, 2022 08:00 ET
|
Eyenovia, Inc.
NEW YORK, June 07, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of late-stage microdose array print (MAP™)...
Eyenovia Reports First Quarter 2022 Financial Results
May 12, 2022 16:05 ET
|
Eyenovia, Inc.
Mydcombi™ NDA resubmission on track for Q3 2022 Phase 3 VISION-2 study evaluating MicroLine as an on-demand treatment for improving near vision (presbyopia) progressing as planned; topline data...
Eyenovia to Report First Quarter 2022 Results on Thursday, May 12
May 05, 2022 08:00 ET
|
Eyenovia, Inc.
NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) therapeutics,...
Eyenovia CEO, CMO and Chairman Dr. Sean Ianchulev to Present at Eyecelerator @ American Society of Cataract and Refractive Surgery (ASCRS) 2022
April 20, 2022 08:00 ET
|
Eyenovia, Inc.
NEW YORK, April 20, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) investigational...
Eyenovia Announces Poster Presentation at the 2022 American Society of Cataract and Refractive Surgery Annual Meeting
April 19, 2022 08:00 ET
|
Eyenovia, Inc.
NEW YORK, April 19, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) therapeutics, today...